Excitement around Unity's longevity drug might have been short-lived
Yesterday, the highest-profile company in biotech’s nascent longevity industry released some bad news: Its lead drug, meant to battle the symptoms of aging, looked no different from placebo in a clinical trial.
As STAT’s Adam Feuerstein reports, this is bad for Unity. The company’s baseline promise is that it can dial back the symptoms of aging by killing the old, or senescent, cells that collect in the body. To test that, it enrolled 183 patients with moderate to severe osteoarthritis and gave them one of three doses or placebo. No amount of Unity’s drug moved the needle on a measurement of pain.
For its part, the company believes the its foundational principles remain sound. Investors might be less convinced. Unity's share price fell about 68%.
Read more.
As STAT’s Adam Feuerstein reports, this is bad for Unity. The company’s baseline promise is that it can dial back the symptoms of aging by killing the old, or senescent, cells that collect in the body. To test that, it enrolled 183 patients with moderate to severe osteoarthritis and gave them one of three doses or placebo. No amount of Unity’s drug moved the needle on a measurement of pain.
For its part, the company believes the its foundational principles remain sound. Investors might be less convinced. Unity's share price fell about 68%.
Read more.
.png)
No hay comentarios:
Publicar un comentario